A Platform for Targeted Degradation of Disordered Proteins
Portera’s small molecules are purpose-built to target proteins that lack defined structure — disordered proteins that play a central role in neurodegenerative diseases, e.g. α-synuclein in Parkinson’s Disease.
Our 20S proteasome enhancers precisely bind, potentiate, and drive the degradation of these elusive, unstructured targets. The result: a new therapeutic modality aimed at the root causes of previously untreatable diseases.
